BMRN
BioMarin Pharmaceutical Inc.
Healthcare
12/09/2014
Presented
| Date | 12/02/2014 |
| Price | $92.27 |
| Market Cap | $0.01B |
| Ent Value | $0.01B |
| P/E Ratio | N/A |
| Book Value | $10.23 |
| Div Yield | 0% |
| Shares O/S | 147.05M |
| Ave Daily Vol | 1,140,000 |
| Short Int | 3.14% |
Current
| Price | $70.46 |
| Market Cap | $13.41B |
| BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California. |
Public traded companies mentioned herein: Companies mentioned: BioMarin Pharmaceuticals (BMRN) and Prosensa (RNA).
Highlights
The presenter sees shares of BioMarin as offering exposure to one of the more attractive pipelines in biotech at a very reasonable valuation. With an existing approved product portfolio/ base business worth about $60-$70 per share alone, BioMarin additionally has a handful of attractive compounds focused on orphan diseases in the pipeline, many of which are enzyme replacement therapies with a high probability of success based on established history.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.